Results 71 to 80 of about 3,259,919 (360)

Clinical application of combination [11C]C-methionine and [13N]N-ammonia PET/CT in recurrent functional pituitary adenomas with negative MRI or [18F]F-FDG PET/CT

open access: yesBMC Endocrine Disorders
Background We assessed the value of positron emission tomography/computed tomography (PET/CT) with [13N]N-ammonia ([13N]N-NH3) and [11C]C-methionine ([11C]C-MET) for the evaluation and management of recurrent secreting pituitary adenoma, which could not ...
Zongming Wang   +6 more
doaj   +1 more source

Chemotherapy-Induced Regression of an Adrenocorticotropin-Secreting Pituitary Carcinoma Accompanied by Secondary Adrenal Insufficiency

open access: yesCase Reports in Endocrinology, 2013
Purpose. Adrenocorticotropin- (ACTH-) secreting pituitary carcinomas are rare and require multimodality treatment. The aim of this study was to report the response to various therapies and discuss the potential development of secondary adrenal ...
Robert Frank Cornell   +9 more
doaj   +1 more source

Growth Hormone (GH)-Releasing Peptide Stimulation of GH Release from Human Somatotroph Adenoma Cells: Interaction with GH-Releasing Hormone, Thyrotropin- Releasing Hormone, and Octreotide. [PDF]

open access: yes, 1994
The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism.
Brockmeier, S.   +7 more
core   +1 more source

Stress‐Induced Activation of Prolactin‐NR4A1‐Midkine Axis Exacerbates Skin Inflammation

open access: yesAdvanced Science, EarlyView.
Chronic psychological stress activates prolactin signaling to reprogram dermal fibroblasts into APCDD1+ inflammatory effectors via NR4A1, driving midkine secretion. This paracrine hub amplifies keratinocyte proliferation and immune recruitment, thus exacerbating skin inflammation.
Zhiguo Li   +18 more
wiley   +1 more source

Full Issue: Volume 13, Issue 1 - Winter 2018 [PDF]

open access: yes, 2018
Full Issue: Volume 13, Issue 1 - Winter ...

core   +1 more source

Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal alpha-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition [PDF]

open access: yes, 2012
PMCID: PMC3534021This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Laenger   +62 more
core   +3 more sources

Drp1‐Mediated Mitochondrial Metabolic Dysfunction Inhibits the Tumor Growth of Pituitary Adenomas [PDF]

open access: hybrid, 2022
Kexia Fan   +11 more
openalex   +1 more source

TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile

open access: yesAdvanced Science, EarlyView.
TSHR is highly expressed in differentiated thyroid cancer (DTC), making it an ideal target for adoptive immune cell therapy. A novel Ligand‐based TSH‐CAR‐T cell approach effectively eradicated TSHR‐positive thyroid tumors in vitro and accomplished full remission in tumor models with favorable safety profile, highlighting that TSH‐CAR‐T cells could ...
Fei Wang   +10 more
wiley   +1 more source

Whole-Exome Sequencing Study of Thyrotropin-Secreting Pituitary Adenomas [PDF]

open access: yes, 2018
学位記番号 ...
Santosh, Sapkota   +2 more
core  

Unexpectedly High Incidence of Immune‐Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab‐Including Chemotherapy

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Nivolumab‐including chemotherapy (nivo‐CTX) for stage IV gastric cancer (GC) may increase the chance of conversion surgery but risk of immune‐related adverse events (irAEs) during perioperative period remains unclear. Methods We examined irAEs in 36 patients with marginally resectable GC who received nivo‐CTX followed by surgery ...
Masashi Nishino   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy